Company Overview
RAPT Therapeutics Inc functions as a clinical-stage immunology-based biopharmaceutical company dedicated to the discovery, development, and commercialization of oral small molecule therapies designed for patients facing unmet medical needs in oncology and inflammatory diseases within the United States. This operational model places the company firmly within the Healthcare sector, specifically the Biotechnology industry, where it navigates a high-risk, high-reward landscape characterized by significant regulatory hurdles and the necessity for substantial research and development expenditures prior to generating revenue. The company currently commands a market capitalization of $1.68B while employing approximately 60 individuals to drive its specialized scientific mission. These financial figures and headcount indicate that RAPT operates as a capital-intensive entity with a relatively lean workforce, typical of early-to-mid stage biotechnology firms that prioritize intellectual property and clinical trial progression over large-scale manufacturing operations or extensive administrative overheads at this stage of growth.
Financial Health
The company reports no reported revenue (TTM) and a net income (TTM) of $-105,637,000, resulting in an EBITDA of $-111,664,000, which highlights a cost structure dominated by heavy investment in clinical trials and operational expenses rather than sales efficiency. The free cash flow stands at $-46,387,500, indicating that the company is currently burning cash to fund its development pipeline, a condition that necessitates continuous access to external capital markets or existing cash reserves to maintain operations. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting a standard characteristic for pre-revenue biotechnology companies where no commercial sales have yet occurred to generate positive margins. Regarding liquidity and leverage, the company holds $157.34M in cash against a total debt obligation of $2.60M, supported by a current ratio of 12.04 which suggests a highly conservative balance sheet with ample short-term assets to cover liabilities. The debt-to-equity ratio is listed at 1.71, a figure that requires careful interpretation in the context of a firm with no revenue, suggesting a complex capital structure often seen in leveraged buyouts or specific financing arrangements for clinical-stage assets. Return on Equity is -85.4% and Return on Assets is -51.3%, metrics that mathematically reflect the dilutive nature of losses relative to the company's equity base and asset holdings, revealing that management has not yet achieved profitability or positive return generation from its deployed capital.
Valuation Assessment
The trailing twelve-month P/E ratio is N/A due to negative earnings, while the forward P/E is -21.38, a valuation metric that is technically distorted by current losses and implies that traditional price-to-earnings comparisons are not applicable for assessing current market expectations at this stage. The price-to-book ratio is 6.43, indicating that the market values the company at a significant premium over its tangible book value, a common occurrence in biotechnology where the primary assets are intellectual property and clinical data rather than physical infrastructure. The price-to-sales ratio is N/A because the company has no sales history, and the EV/EBITDA stands at -13.01, further underscoring that standard enterprise value multiples cannot be used to gauge relative value against peers with positive cash flows. The stock's 52-week trading range has fluctuated between a low of $5.67 and a high of $58.02, illustrating extreme volatility often associated with clinical-stage assets awaiting pivotal data readouts. The current price position relative to this wide range cannot be precisely calculated without a real-time price input, but the historical spread demonstrates the significant risk premium investors demand for uncertainty regarding future clinical outcomes. The beta is 0.44, which suggests that the stock's price volatility is historically lower than the broader market, a counter-intuitive observation for a biotechnology firm that may be driven more by binary clinical event risks than general market fluctuations.
Growth & Income
The revenue growth (YoY) is N/A and earnings growth (YoY) is N/A, as the company has not yet generated commercial revenue to establish a historical growth trajectory or earnings baseline. Consequently, it is not possible to determine if earnings are growing faster or slower than revenue because both metrics are currently non-existent in the financial records. As a non-dividend payer, the company offers a dividend yield of N/A and maintains a payout ratio of 0.0%, meaning that all available cash flow is theoretically reinvested into research and development activities rather than distributed to shareholders. This reinvestment strategy is standard for clinical-stage immunology companies that must prioritize funding their drug development pipelines over providing immediate income to investors. The overall growth and income profile is characterized by the absence of current financial returns and growth rates, with the company's value entirely contingent on the future success of its oral small molecule therapies in oncology and inflammatory disease markets.